ENLV
Enlivex Ltd.
NASDAQ · Healthcare · Biotechnology · IL
$0.21
+1.17%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -37.4%
- EBIT
- -33.9%
- EPS
- +8021.5%
- Free cash flow
- -28.3%
- Operating cash flow
- -26.2%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- —
- EBITDA
- -1.4%
- EBIT
- +3.5%
- Net income
- +8329.2%
- EPS
- +3804.1%
- Free cash flow
- +20.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026